What is Wuhan Keqian Biology Co.,Ltd's (688526.SS) StockRank?

MoatMap's StockRank for Wuhan Keqian Biology Co.,Ltd (688526.SS) is 83/100, with a Strong Buy signal. This is a composite score combining Quality (71), Value (58), and Momentum (41) factor ranks across MoatMap's 19,000+ stock universe.

Does Wuhan Keqian Biology Co.,Ltd have an economic moat?

Wuhan Keqian Biology Co.,Ltd (688526.SS) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Wuhan Keqian Biology Co.,Ltd a buy, hold, or sell?

MoatMap's current signal for Wuhan Keqian Biology Co.,Ltd (688526.SS) is Strong Buy, based on a StockRank of 83/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Wuhan Keqian Biology Co.,Ltd in?

Wuhan Keqian Biology Co.,Ltd (688526.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

688526.SS

STRONG BUYREMOVE

Wuhan Keqian Biology Co.,Ltd · Healthcare · China · $906M · Avg Vol: $3M/d

StockRank

P/E (TTM)

15.1x

ROE

9.3%

D/E

0.0x

Dividend %

5.1%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Wuhan Keqian Biology specializes in animal vaccines. Despite decent quality metrics, its business model is tied to swine and livestock cycles rather than any of our high-conviction structural macro themes.

COMPANY DESCRIPTION

Wuhan Keqian Biology Co., Ltd. researches, develops, and manufactures veterinary biological products, primarily swine vaccines. The company holds a leading market share in China's swine pseudorabies and parvovirus vaccine markets, backed by strong academic research ties. It is a high-margin animal health leader with a robust R&D pipeline tailored to the domestic livestock industry.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	148M	157M	139M	140M	-1.7%
EPS	0.13	0.13	0.12	0.13	0.8%
Shares	466M	466M	466M	466M	-0.0%
Debt	41M	43M	1M	987,300	-71.2%
Equity	517M	567M	582M	626M	6.6%
Op CF	63M	80M	58M	69M	3.4%
Inv CF	-94M	-49M	14M	-96M	—
Fin CF	17M	-15M	-74M	-27M	—

PRICE (1M)-12.0%

SMA 50SMA 200

$1.87

RSI (14)

31.7

52W High

$2.88

From 52W High

0.7%

SCORE BREAKDOWN

Quality

ROIC

11.1%76.4

ROE

9.3%70.1

GP/Assets

12.6%31.1

Op. Margin

38.9%96.2

FCF/Assets

3.6%64.2

Piotroski

—55.8

Int. Cover

50.0x91.4

D/E Ratio

0.00x96.7

Current Ratio

7.42x81.3

Value

P/E (TTM)

15.1x72.3

EV/EBITDA

8.4x46.9

P/FCF

243.7x33.1

P/B

1.4x69.5

P/S

6.3x34.7

Div Yield

5.1%91.1

Momentum

52W High %

65%48.3

RS 6M

-23%50.6

SMA 50/200

0.90x33.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+35%45.3

Q Growth

-27%19.9

FUNDAMENTALS

Market Cap

$906M

P/E (Forward)

11.2x

Gross Margin

64.7%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 688526.SS are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
688526.SS	Wuhan Keqian Biology Co.,Ltd(you)	$906M	83	STRONG BUY
6826.HK	Shanghai Haohai Biological Technology Co., Ltd.	$523M	82	STRONG BUY
300841.SZ	Chengdu Kanghua Biological Products Co., Ltd.	$917M	67	BUY
2142.HK	HBM Holdings Limited	$1.2B	94	STRONG BUY
301047.SZ	Sino Biological,Inc.	$1.1B	70	BUY
688046.SS	GemPharmatech Co., Ltd.	$1.2B	70	BUY
603566.SS	Pulike Biological Engineering, Inc.	$543M	74	BUY
300009.SZ	Anhui Anke Biotechnology (Group) Co., Ltd.	$2.1B	86	STRONG BUY
2509.HK	Qyuns Therapeutics Co., Ltd.	$483M	74	BUY
3880.HK	Medtide Inc.	$393M	89	STRONG BUY

Peer medians: ROE 4.7% · P/E 27.9x · Gross margin 53.0%

Wuhan Keqian Biology Co.,Ltd (688526.SS) — Stock Score Summary

Wuhan Keqian Biology Co.,Ltd (688526.SS) has a MoatMap StockRank of 83/100 based on Quality (71/100), Value (58/100), and Momentum (41/100) factor scores. The current signal is STRONG BUY. Wuhan Keqian Biology specializes in animal vaccines. Despite decent quality metrics, its business model is tied to swine and livestock cycles rather than any of our high-conviction structural macro themes.

Key Financial Metrics

Price	$1.87
Market Cap	$906M
P/E (TTM)	15.10
P/E (Forward)	11.22
Price/Book	1.37
Return on Equity	9.3%
Return on Invested Capital	11.1%
Debt/Equity	0.15
Gross Margin	64.7%
Operating Margin	38.9%
Revenue Growth	-7.2%
Dividend Yield	5.1%
Free Cash Flow	$4M

Wuhan Keqian Biology Co.,Ltd operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Wuhan Keqian Biology Co.,Ltd’s (688526.SS) StockRank?: MoatMap’s StockRank for Wuhan Keqian Biology Co.,Ltd (688526.SS) is 83/100, with a Strong Buy signal. It is a composite of Quality (71), Value (58), and Momentum (41) factor ranks across MoatMap’s 19,000+ stock universe.
Does Wuhan Keqian Biology Co.,Ltd have an economic moat?: Wuhan Keqian Biology Co.,Ltd (688526.SS) has a Quality factor score of 71/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Wuhan Keqian Biology Co.,Ltd a buy, hold, or sell?: MoatMap’s current signal for Wuhan Keqian Biology Co.,Ltd (688526.SS) is Strong Buy, based on a StockRank of 83/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Wuhan Keqian Biology Co.,Ltd in?: Wuhan Keqian Biology Co.,Ltd (688526.SS) operates in the Healthcare sector, specifically the Biotechnology industry (China).